ASCO 2020：11项中国研究入选口头调查结果，17项Poster调查结果

深受全球新冠疫情严重影响，月末初于5月末29日~6月末2日在芝加哥举办地的美国针灸学会（ASCO）大会今年将首次以线上形式举办，这是现在最大规模的线上盛会。今天，开会的摘录作答发布，共计103个sessions，中都国共计有11项研究成果入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或拉帕替尼加卡培他中洲用做HER2+集中于持续性乳腺肝癌（PHOEBE）：一项III期随机检验。

艺术节：集中于持续性乳腺肝癌

写作者：中都国医学科学院养老院徐兵河客座教授、马飞客座教授，复旦大学附属养老院胡夕春客座教授等

摘录号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阳持续性乳腺肝癌标准化化疗后卡培他中洲确保快节奏抗生素的III期检验（SYSUCC-001）。

艺术节：乳腺肝癌—全局/地带/常规化疗

写作者：中都山大学禁毒中都心称王树森客座教授等

摘录号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

运用集中于持续性脑干的表现型特征来预测循环系统中都循环DNA扫描的均值: 新方法对抗从前对手

艺术节：新方法消除从前缺陷

写作者：朱美芹 朱德兰等

摘录号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

罗萨非尼对科特迪瓦拉非尼作为末期肝线粒体肝癌的一线化疗：一项开放关键字、随机、多中都心II/III期检验。

艺术节：肠肾脏肝癌—肠胃膀胱、肾上腺和绝

写作者：东南大学索科利夫卡养老院毕锋客座教授、中都国人民解放军新华养老院秦叔逵客座教授等

摘录号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中都国末期肝肝癌病症阿帕替尼中卫化疗：一项随机、临床实验对应、双盲III期研究成果

艺术节：肠肾脏肝癌—肠胃膀胱、肾上腺和绝

写作者：中都国人民解放军新华养老院秦叔逵客座教授、东南大学索科利夫卡养老院朱秋客座教授等

摘录号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

末期复发持续性卵巢肝癌二次线粒体减灭术的一项随机III期检验：SOC1 / SGOG-OV2。

专题：妇产科肝乳癌

写作者：复旦大学附属中都山养老院臧荣余客座教授等

摘录：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈肝癌根治持续性输卵管输卵管后常规化疗中都的序贯放抗生素对比基本上恶性肿瘤或实时放抗生素（STARS研究成果）：一项随机、对应、开放关键字的III期检验。

开会：妇产科肝乳癌

写作者：中都山大学禁毒中都心大白客座教授、刘继红客座教授等

摘录号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：常规吉非替尼对比抗生素用做可切除的EGFR特异性的N1-N2期NSCLC-随机III期针灸检验的之后相比较求生研究。

专题：膀胱肝癌—非小线粒体全局-地带/小线粒体/其他腰部

写作者：广东省人民养老院吴一龙客座教授等

摘录号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR特异性寡集中于非小线粒体膀胱肝癌病症一线赖氨酸磷酸化肽倡议或不倡议更进一步第一线全局恶性肿瘤：III期开放关键字针灸随机检验（SINDAS）的中都期结果（NCT02893332）。

专题：膀胱肝癌-非小线粒体集中于

写作者：成都市人民养老院曾铭客座教授等

摘录：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序持续性死亡-1（PD-1）的人源化IgG4酵母菌倡议阿昔替尼用做集中于持续性皮肤丙型肝炎病症的Ib期研究成果的总求生期和有机体标志物研究。

专题：丙型肝炎/皮肤肝癌

写作者：北京大学养老院郭军、盛锡楠客座教授等

摘录：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全持续性和结果：通用CAR-T线粒体首次人体检验化疗复发/难治持续性T线粒体急持续性淋巴线粒体帕金森氏症（r/r T-ALL）的安全持续性和。开会：技术开发中都的化疗电子技术-免疫化疗。写作者：称王林欣等摘录：3013剧照：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在末期膀胱粒状线粒体肝癌病症中都的系统设计：一项随机的开放关键字II期检验（ORIENT-2）。开会：肠肾脏肝癌-肠胃膀胱肝癌、肾上腺肝癌和绝道肝癌写作者：徐建明客座教授等摘录：4511剧照：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异持续性CAR-T线粒体对脾脏母线粒体瘤的禁绝持续性化疗开会：中都枢神经系统写作者：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东摘录：2522剧照。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在末期错配修复缺陷病症中都的系统设计开会：技术开发中都的化疗学-免疫化疗写作者：沈琳客座教授等摘录：3021剧照。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 增生CD7-CART化疗复发/难治持续性ACUTE淋巴线粒体帕金森氏症/淋巴瘤的首例人体针灸检验开会: 技术开发持续性化疗学-免疫化疗写作者简介：张明志，杨林等摘录：3026剧照: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度酮（T）倡议系统设计做末期实体瘤病症的Ib期研究成果开会：发展持续性化疗学--底物靶向药物和生态学写作者：龚继芳，沈琳客座教授等摘录：3523剧照：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin倡议紫杉醇和nedaplatin化疗复发持续性或集中于持续性膀胱粒状线粒体肝癌（ESCC）病症的II期研究成果。开会：肠肾脏肝癌-肠胃膀胱、肾上腺和绝道肝癌的研究成果写作者：称王志强，朱玉红，称王德申，称王凤华，任超，谭琼 称王志强、朱玉红、称王德深、称王凤华、任超、谭琼摘录：4522剧照：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.开会：肠肾脏肝癌-肠胃膀胱肝癌、肾上腺肝癌和绝管肝癌的中卫化疗写作者：宋艳等摘录：4524剧照：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体外侧RNA均值用做初始前列腺时扫描高等级肝癌的尿液外体外侧RNA均值：一项多中都心的回顾持续性研究成果开会：泌尿生殖细胞肝乳癌----肝癌、睾丸肝癌和肝癌写作者简介：Liaoyuan Li等摘录：5522剧照。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 全局末期宫颈肝癌并发抗生素后的常规抗生素开会: 妇产科肝乳癌写作者简介： 朱珉珉等摘录：6031剧照：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼化疗甲状腺脾脏持续性肝癌的相关持续性：基于ALTER01031检验的研究。会话：粒状写作者：唐山市养老院霸道客座教授摘录：6526剧照。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼化疗后病症第一集的严重影响: ALTER01031的亚组研究开会：粒状写作者：唐山市养老院霸道客座教授摘录：6527剧照。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA研究预测I-IIIA期非小线粒体膀胱肝癌（NSCLC）病症术后复发: GASTO1035和GASTO1018的结果开会：膀胱肝癌-非小线粒体全局-地带持续性/小线粒体/小线粒体/其他胸科肝乳癌写作者：Si-Yu Wang等摘录：9023剧照：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小线粒体膀胱肝癌（NSCLC）中都EGFR赖氨酸磷酸化肽的新型耐药有助于开会:膀胱肝癌-非小线粒体集中于持续性膀胱肝癌写作者简介：赵昕，金小妹，满宇，欧西厢记，华宝，薛武，杨少，范敏 赵昕、金小妹、满宇、欧西厢记、华宝、薛武、杨绍、范敏摘录：9528剧照：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1检验中都末期丙型肝炎总求生的替代终点开会：丙型肝炎/皮肤肝癌写作者：聂润聪，袁书强，朱元芳，陈英波，周志伟 聂润聪、袁书强、朱元芳、陈英波、周志伟摘录：10030剧照：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼化疗复发或集中于持续性原发持续性恶持续性骨头病症的II期研究成果开会： 病症写作者：唐丽娜，牛晓辉，称王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、称朱高煦、蔡启庆、涂崇奇、范正福、杨瑶摘录：11525剧照。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 先期口碑安罗替尼在末期病症病症多线化疗中都的安全持续性和。开会：病症写作者：姚伟涛，称王侯强，张瑞，称王林，杜新辉，田志浩，牛晓颖 姚伟涛、称王侯强、张瑞、称王鑫、杜鑫辉、田志超、牛晓英摘录：11526剧照：414